At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 150 enrolled
Drug / intervention
Ketotifen/Indomethacin +1 moredrug
Likely dose
Ketotifen/Indomethacin 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults
In Brief
A Phase 3 clinical trial evaluating Ketotifen/Indomethacin and Placebo for COVID-19 Respiratory Infection. Completed, enrolled 150 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Respiratory Infection
CountriesNepal
CollaboratorsNational University of Singapore
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartMay 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedAug 16, 2021
Enrollment StartMay 3, 2022
Primary CompletionJun 20, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.9 years ago
Interventions
Ketotifen/Indomethacindrug
2 mg tablet, 75 mg SR tablet
Placebodrug
Matching placebo tablet